|
Wed, 11/10/2021 - 12:40 |
Immunotherapy May Yield Longer Treatment-free Survival Than Targeted Therapy in Advanced Renal Cell Carcinoma Patients |
American Associ... |
|
Thu, 09/16/2021 - 22:39 |
Update on INVICTUS Trial Shows Improved Overall Median Survival in GIST Patients Using Ripretinib |
Fox Chase |
|
Fri, 05/15/2020 - 17:04 |
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors |
FDA |
|
Mon, 02/17/2020 - 05:18 |
Kidney cancer drug gets initial no for NHS England |
Cancer Research UK |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Mon, 10/28/2019 - 10:04 |
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
|
Wed, 08/14/2019 - 08:45 |
Exercise associated with benefit to patients with advanced colorectal cancer |
Dana Farber |
|
Wed, 08/07/2019 - 00:10 |
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
|
Thu, 07/18/2019 - 17:03 |
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR D842V Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
|
Fri, 06/14/2019 - 13:10 |
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
|
Sat, 06/01/2019 - 05:20 |
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib |
Blueprint Medicines |
|
Thu, 04/25/2019 - 07:19 |
Exelixis Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX (Cabozantinib) for Advanced Renal Cell Carcinoma |
Exelixis |
|
Fri, 04/05/2019 - 16:43 |
Kidney cancer immunotherapy combo approved for NHS use in England |
Cancer Research UK |
|
Tue, 02/19/2019 - 09:36 |
Drug combination boosts kidney cancer survival in trials |
Cancer Research UK |
|
Sat, 02/16/2019 - 00:19 |
Drug combination may become new standard treatment for advanced kidney cancer |
Dana Farber |
|
Thu, 12/13/2018 - 08:06 |
Immunotherapy combo not approved for advanced kidney cancer patients on the NHS |
Cancer Research UK |
|
Sun, 10/21/2018 - 16:16 |
Positive Data from Randomized Phase III Study Suggests That a Combination of Immunotherapy Drugs Can Help Some People with Advanced Kidney Cancer |
MSKCC |
|
Tue, 04/10/2018 - 11:33 |
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery |
Pfizer |
|
Wed, 03/21/2018 - 16:42 |
Pivotal Results from Phase III Trial Show That the Combination of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer |
MSKCC |
|
Tue, 03/20/2018 - 08:14 |
Potential Cognitive Effects of Molecularly Targeted Drugs in Children May be Reversible With Therapy |
American Associ... |
|
Fri, 03/16/2018 - 08:49 |
Cancer Diagnosis? Learn Why Second Opinions Matter |
Roswell Park Ca... |
|
Fri, 02/23/2018 - 09:49 |
Pfizer Announces Update on European Marketing Authorization Application for SUTENT (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma |
Pfizer |
|
Mon, 02/05/2018 - 23:05 |
Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer |
Rocheusa |
|
Tue, 12/19/2017 - 01:52 |
Backed by Dana-Farber research, FDA approves new indication for a kidney cancer drug |
Dana Farber |
|
Mon, 12/11/2017 - 00:24 |
Atezolizumab plus Avastin Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study |
Chugai |
